STOCK TITAN

State Street (SNDX holder) discloses 5.3% Syndax Pharmaceuticals ownership stake

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

STATE STREET CORPORATION reported a significant ownership stake in Syndax Pharmaceuticals Inc. common stock. As of 12/31/2025, it beneficially owned 4,596,552 shares, representing 5.3% of the company’s common stock.

State Street reported no sole voting or dispositive power, but shared voting power over 4,341,322 shares and shared dispositive power over 4,596,552 shares. The position is certified as being held in the ordinary course of business and not for influencing control of Syndax.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



STATE STREET CORPORATION
Signature:ELIZABETH SCHAEFER
Name/Title:SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
Date:02/09/2026

FAQ

What ownership stake does State Street report in Syndax Pharmaceuticals (SNDX)?

State Street Corporation reports beneficial ownership of 4,596,552 shares of Syndax Pharmaceuticals common stock, representing 5.3% of the outstanding class as of December 31, 2025. This makes State Street a significant institutional holder of SNDX shares.

How much voting power does State Street have in SNDX shares?

State Street reports no sole voting power, but shared voting power over 4,341,322 shares of Syndax Pharmaceuticals common stock. This means voting decisions on these shares are exercised jointly, consistent with State Street’s role as an institutional asset manager.

How many Syndax (SNDX) shares can State Street dispose of?

State Street reports no sole dispositive power, but shared dispositive power over 4,596,552 shares of Syndax common stock. Shared dispositive power indicates State Street participates in decisions about selling or otherwise disposing of these shares on behalf of clients.

Is State Street’s Syndax (SNDX) stake intended to influence control?

State Street certifies the shares were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing control of Syndax. The holding is characterized as a passive institutional investment position.

Who is the reporting person for this 5.3% Syndax (SNDX) ownership?

The reporting person is State Street Corporation, organized in Massachusetts, with a principal office at One Congress Street, Suite 1, Boston, MA 02114. Several State Street Global Advisors entities are identified as relevant investment adviser subsidiaries.

What subsidiaries are associated with State Street’s SNDX holdings?

Associated entities include SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd., each identified as investment advisers involved with the reported holdings.
Syndax Pharmaceuticals Inc

NASDAQ:SNDX

SNDX Rankings

SNDX Latest News

SNDX Latest SEC Filings

SNDX Stock Data

1.83B
85.79M
1.29%
120.98%
24.28%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK